Fort Worth, Tex.—Aggressive identification and treatment strategies have led to an overall cure rate for childhood malignancies of greater than 80%, but an increasing number of surviving patients are developing therapy-related toxicities later in life.
At the 2019 annual meeting of the Hematology/Oncology Pharmacy Association (HOPA), Joseph Sciasci, PharmD, and Mary Mably, RPh, reviewed strategies for reducing the impact of late and specific effects of treatment on young adult and